Sepsis Clinical Trial
Official title:
Treatment With Cotrimoxazole vs. Vancomycin for Infections Caused by Methicillin-resistant Staphylococcus Aureus: Randomized Controlled Trial
Methicillin-resistant Staphylococcus aureus (SA) is a major pathogen causing mainly
health-care associated infections and, lately, also community acquired infections. Few
treatment choices exist to treat these infections. The currently recommended antibiotics for
these infections are glycopeptides (vancomycin or teicoplanin). Glycopeptide treatment hs
several disadvantages. It is a last resort antibiotic family that should be reserved for the
future; Vancomycin is less effective that beta-lactam drugs for SA infections susceptible to
both agents; treatment can only be given intravenously; and use of vancomycin has led to the
development of SA strains with partial or complete resistance to vancomycin. Cotrimoxazole
is an old antibiotic active against most strains of MRSA, depending on local epidemiology.
Study hypothesis: The purpose of this study is to show that cotrimoxazole is as effective as
treatment with vancomycin for invasive MRSA infections.
We plan a randomized controlled trial comparing treatment with cotrimoxazole vs. vancomycin
for invasive MRSA infections. The primary efficacy outcome we will assess will be
Improvement or cure with or without antibiotic modifications, defined as: survival at 7 days
post randomization with resolution of fever (<38 for two consecutive days) and resolution of
hypotension (>90 systolic without need for vasopressor support); and physician's assessment
that the primary infection was improved or cured. The primary safety outcome will be
all-cause 30-day survival.
Staphylococcus aureus (SA) is a major pathogen causing community-acquired and health-care
associated infections. In hospitals, SA infections are associated with a significant burden;
in-hospital mortality during the last 15 years following SA bacteremia in Beilinson hospital
was 38% and did not decrease in recent years. Resistance to beta-lactams is widely prevalent
in hospitals (57% of all SA isolates causing bacteremia at our center). The drug of choice
currently recommended for these infections is a glycopeptide (vancomycin or teicoplanin).
Cotrimoxazole (trimethoprim-sulfamethoxazole) is a relatively 'old' drug commonly used for
urinary tract infections. Invitro, it is active against SA, including methicillin-resistance
Staphylococcus aureus (MRSA) strains and its activity against SA is bactericidal.
Trimethoprim alone is bactericidal against SA, while sulphamethoxazole alone is relatively
inactive and their combination is synergistic both in-vitro and invivo. The prevalence of
cotrimoxazole-susceptible SA varies locally. At our center, 97% of SA strains causing
bacteremia in 2004 were susceptible to cotrimoxazole. Community-acquired MRSA, prevalent in
the United States as a cause for severe skin and soft tissue infections, has not been
described in Israel.
Several reasons exist to search for antibiotics other than vancomycin for MRSA infections.
Vancomycin is less effective that beta-lactam drugs for SA infections susceptible to both
agents. It is the last resort antibiotic for MRSA infections out of the currently
recommended bactericidal antibiotics for invasive infections. Use of vancomycin has led to
the development of SA strains with partial or complete resistance to vancomycin (VISA and
VRSA, respectively). Vancomycin use is associated with the appearance of
vancomycin-resistant enterococcus (VRE) species. Nosocomial infections with VISA and VRE are
difficult to treat and may spread rapidly in the hospital. 10 Finally, vancomycin cannot be
administered orally.
Limited evidence supports the efficacy of cotrimoxazole for MRSA infections, with paucity of
data for high-burden invasive infections. Cotrimoxazole is probably inferior to vancomycin
for methicillin-susceptible SA. ; thus we may infer indirectly its inferiority to
methicillin and drugs alike for MRSA infections. Cotrimoxazole may be less effective than
glycopeptides and oxacillin for left-sided endocarditis. No evidence exists to support the
use of cotrimoxazole empirically for the treatment of suspected SA infections in the
hospital.
We plan an open label single-center pragmatic randomized controlled trial to compare
cotrimoxazole to vancomycin. We will include patients with documented or highly suspected
MRSA infections, according to pre-defined risk factors. We chose to target this patient
population to assess the efficacy of cotrimoxazole both empirically and for documented
infections.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
| Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
| Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
| Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
| Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
| Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
| Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
| Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
| Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
| Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
| Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
| Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
| Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
| Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
| Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
| Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |